Five Star Equities Issues New Research Reports on CTRL, TRMB, VICL and VTUS


Follow this company

Companies Mentioned

NASDAQ:CTRL / NASDAQ:TRMB / NASDAQ:VICL / NASDAQ:VTUS
02/13/2014 [ACCESSWIRE]

Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.

Control4 Corp. (NASDAQ: CTRL) shares spiked 16.18 percent to close at $23.41 a share Wednesday. The stock traded between $20.68 and $24.00 on volume of 2.0 million shares traded. The company reported revenues were $35.8 million for the fourth quarter of 2013, an increase of 17.0 percent when compared to a year ago. Shares of Control4 are up approximately 30.0 percent year-to-date.

Get more information on Control4and free access to the in-depth equity report at:  
www.FiveStarEquities.com/CTRL

Trimble Navigation Limited (NASDAQ: TRMB) shares surged 14.01 percent to close at $37.19 a share Wednesday. The stock traded between $34.36 and $37.42 on volume 6.88 million shares traded. The company reported a GAAP net income of $60.0 million for the fourth quarter of 2013, an increase of 81.0 percent when compared to a year ago. Shares of Trimble Navigation are up approximately 7.0 percent year-to-date.

Get more information on Trimble Navigation free access to the in-depth equity report at:  
www.FiveStarEquities.com/TRMB

Vical Incorporated (NASDAQ: VICL) shares jumped 10.29 percent to close at $1.50 a share Wednesday. The stock traded between $1.41 and $1.66 on volume of 5.17 million shares traded. The company reported revenues were $3.15 million for the fourth quarter of 2013, an increase of 35.0 percent when compared to a year ago. Shares of Vical are up approximately 27.0 percent year-to-date.

Get more information on Vical and free access to the in-depth equity report at:  
www.FiveStarEquities.com/VICL

Ventrus Biosciences Inc. (NASDAQ: VTUS) shares tumbled 63.01 percent to close at $1.62 a share Wednesday. The stock traded between $1.47 and $1.78 on volume 18.06 million shares traded. The company announced that its diltiazem hydrochloride cream, a treatment for anal fissure pain, failed to meet its primary endpoint in a recent Phase 3 clinical trial. Shares of Ventrus Biosciences are down approximately 58.0 percent year-to-date.

Get more information on Ventrus Biosciences and free access to the in-depth equity report at:  
www.FiveStarEquities.com/VTUS

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.

Contact:                
Five Star Equities
info@fivestarequities.com

COMMENTS

Leave a comment...
 * 

Your Name
 *